AFP阴性HCC早期筛查和诊断的生物标志物研究进展

摘要/Abstract

摘要： 肝细胞癌的早期诊断和有效治疗对提高生存率和改善预后至关重要。甲胎蛋白是目前应用最广的诊断肝细胞癌的生物学标志物,但临床中发现甲胎蛋白易受一些非肝细胞癌疾病的影响^[1],对于早期肝细胞癌和小肝细胞癌,其诊断能力较低,并且有30%～40%的肝细胞癌患者甲胎蛋白阴性或低于临界值,为了弥补甲胎蛋白的缺点,提高诊断的敏感性和特异度,国内外学者对甲胎蛋白阴性肝细胞癌患者早期筛查和诊断进行了大量的研究,本文对有望用于甲胎蛋白阴性肝细胞癌患者早期辅助诊断的生物学标志物做一综述。

王华, 尹伟, 张云, 李成忠. AFP阴性HCC早期筛查和诊断的生物标志物研究进展[J]. 肝脏, 2022, 27(11): 1242-1246.

参考文献

[1] Chan SL, Mo F, Johnson PJ, et al. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB(Oxford), 2014,16(4):366-372.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021,71(3):209-249.
[3] Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis, 2017,65:15-21.
[4] 原发性肝癌诊疗规范(2019年版). 中国临床医学, 2020,27(01):140-160.
[5] Toyoda H, Kumada T, Tada T, et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci, 2011,102(5):1025-1031.
[6] Zhang Z, Zhang Y, Wang Y, et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther, 2015,9:123-129.
[7] Kumada T, Toyoda H, Tada T, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol, 2014,49(3):555-563.
[8] Chen H, Zhang Y, Li S, et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res,2018,10:1947-1958.
[9] Hu B, Tian X, Sun J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci, 2013,14(12):23559-23580.
[10] Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.Medicine(Baltimore), 2017,96(11):e5811.
[11] Wang X, Zhang W, Liu Y, et al. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer, 2017,12(1):47.
[12] Ji J, Wang H, Li Y, et al. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS ONE, 2016,11(4):e153227.
[13] Liu Z, Wu M, Lin D, et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res, 2020,48(2):1410560401.
[14] Xu F, Zhang L, He W, et al. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Dis Markers, 2021,2021:8868370-8868379.
[15] Feng H, Li B, Li Z, et al. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer, 2021,21(1):401.
[16] 卫荣荣, 王成成, 李大江, 等. 异常凝血酶原对乙型肝炎病毒相关性AFP阴性肝癌的诊断价值研究. 四川大学学报(医学版), 2020,51(03):411-415.
[17] Anborgh PH, Mutrie JC, Tuck AB, et al. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med, 2010,14(8):2037-2044.
[18] Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012,55(2):483-490.
[19] Zhu M, Zheng J, Wu F, et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol, 2020,92(12):3596-3603.
[20] Ge T, Shen Q, Wang N, et al. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol, 2015,32(3):59.
[21] El-Khazragy N, Khalifa MM, Salem AM, et al. Evaluation of Osteopontin and Pokemon genes expression in hepatitis C virus-associated hepatocellular carcinoma. J Cell Biochem, 2018,120(5):7439-7445.
[22] Cheng J, Wang W, Sun C, et al. Meta-Analysis of the Prognostic and Diagnostic Significance of Serum/Plasma Osteopontin in Hepatocellular Carcinoma. J Clin Gastroenterol, 2014,48(9):806-814.
[23] Xiong Y, Xie CR, Zhang S, et al. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res, 2019,11:5745-5756.
[24] Wang T, Zhang KH, Hu PP, et al. Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget, 2016,7(39):64053-64070.
[25] Wang T, Zhang KH, Hu PP, et al. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. Oncotarget, 2017,8(58):97758-97768.
[26] She S, Xiang Y, Yang M, et al. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol, 2015,47(2):543-554.
[27] Ma LN, Liu XY, Lu ZH, et al. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol Lett, 2017,13(5):3457-3464.
[28] Suner A, Carr BI, Akkiz H, et al. C-Reactive protein and platelet-lymphocyte ratio as potential tumor markers in low-alpha-fetoprotein hepatocellular carcinoma. Oncology, 2019,96(1):25-32.
[29] Jing W, Peng R, Zhu M, et al. Differential expression and diagnostic significance of pre-albumin, fibrinogen combined with D-Dimer in AFP-Negative hepatocellular carcinoma. Pathol Oncol Res, 2020,26(3):1669-1676.
[30] Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci, 2019,15(1):221-228.
[31] Huang L, Mo Z, Hu Z, et al. Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma. Cancer Cell Int, 2020,20(1):77.
[32] Li J, Tao H, Zhang E, et al. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma. Cancer Med, 2021,10(14):4844-4854.
[33] Luo CL, Rong Y, Chen H, et al. A logistic regression model for noninvasive prediction of afp-negative hepatocellular carcinoma. Technol Cancer Res Treat, 2019,18:1078114280.
[34] Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016,54(12):1296-1305.
[35] Zhang X, Wang T, Zhang KH, et al. Simple clinical metrics enhance afp to effectively identify cirrhotic patients with complicating hepatocellular carcinoma at various AFP levels. Front Oncol, 2019,9:1478.
[36] Zhu L, Li T, Ma X, et al. A simple noninvasive index can predict hepatocellular carcinoma in patients with chronic hepatitis B. Sci Rep, 2017,7(1):8910-8954.